
The finding that EGF receptor (Epidermal Growth Factor Receptor) and PDGF receptor (Platelet-Derived Growth Factor Receptor) are involved in bone metastases opens up new therapeutic prospects. This new approach should allow the development of new therapeutic agents: EGF R/HER2 inhibitors and PDGF R antagonists.

